Company intelligence / Profile preview

Sugentech

Ownership: Private
Employees: ~145
Development stage: Commercial

Overview

Sugentech has developed and commercialized a range of in vitro diagnostic products including multiplexed immunoblot systems for allergy and autoimmune diagnostics, point-of-care rapid tests for infectious diseases like COVID‑19 and flu, quantitative analyzers for chronic conditions such as diabetes and cardiovascular disease markers. Their Surearly SMART product offers unique multi-hormone analysis for female health management. Products are CE marked/FDA registered where applicable. No clinical trial data typical of therapeutics—products are marketed medical devices.

Therapeutic areas: Infectious DiseasesEndocrinologyImmunologyCardiovascularWomen's Health
Modalities: ImmunoassayAntibodyNanoparticle-based diagnostics
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Sugentech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sugentech.

Explore the full profile